Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Head and Neck Cancer
Interventions
DRUG

Melatonin

Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study

DRUG

Matched Placebo

Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study

Trial Locations (1)

34000

Ubon Ratchathani Cancer Hospital, Ubon Ratchathani

All Listed Sponsors
collaborator

Ubon Ratchathani Cancer Hospital, Ubon Ratchathani

UNKNOWN

collaborator

General Drugs House Co.,LTD.

OTHER

lead

Khon Kaen University

OTHER

NCT02430298 - Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients | Biotech Hunter | Biotech Hunter